65% buyers of institutions opening or closing positions this quarter
33 more new buyers than exits, ownership rose 91.79 percentage points vs the prior quarter, and 2 well-known fund managers in the top 25.
65% buyers of institutions opening or closing positions this quarter
150.6% institutional ownership
22NW, LP portfolio allocation
Institutional ownership vs Biotechnology peers
No Form 4 insider transactions on file
Latest positioning in NKTR across 13F flow, ownership shift, marquee holders, and holder-count growth.
Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in NKTR held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 4.3M | $309.6M | +4155.1% | 22.021% | 0.02% |
| 2 | BVF INC/IL | 2.6M | $184.2M | +64.1% | 13.099% | 5.87% |
| 3 | Two Seas Capital LP | 2.0M | $141.0M | +162.9% | 10.026% | 1.97% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $86.1M | β | 6.126% | 0.00% |
| 5 | TWO SIGMA INVESTMENTS, LP | 931K | $67.0M | +96.8% | 4.763% | 0.05% |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 903K | $65.0M | -22.0% | 4.622% | 0.01% |
| 7 | Prosight Management, LP | 735K | $52.9M | +32.5% | 3.761% | 8.67% |
| 8 | BlackRock, Inc. | 693K | $49.8M | +7.3% | 3.545% | 0.00% |
| 9 | CITADEL ADVISORS LLC | 665K | $47.9M | +36.0% | 3.405% | 0.01% |
| 10 | MORGAN STANLEY | 659K | $47.4M | +16.4% | 3.374% | 0.00% |
| 11 | ARMISTICE CAPITAL, LLC | 578K | $41.6M | -3.0% | 2.958% | 0.74% |
| 12 | Invesco Ltd. | 567K | $40.8M | +21.2% | 2.904% | 0.01% |
| 13 | Sofinnova Investments, Inc. | 510K | $36.7M | +16.2% | 2.608% | 1.39% |
| 14 | Woodline Partners LP | 415K | $29.9M | +299.4% | 2.126% | 0.11% |
| 15 | MILLENNIUM MANAGEMENT LLC | 404K | $29.1M | -11.0% | 2.069% | 0.01% |
| 16 | Bronte Capital Management Pty Ltd. | 401K | $28.8M | β | 2.051% | 2.86% |
| 17 | EMERALD ADVISERS, LLC | 395K | $28.4M | +2.7% | 2.019% | 0.90% |
| 18 | Qube Research & Technologies Ltd | 391K | $28.1M | +20.6% | 1.999% | 0.03% |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 347K | $25.0M | +36.3% | 1.775% | 0.00% |
| 20 | UBS Group AG | 320K | $23.0M | +11.3% | 1.639% | 0.00% |
| 21 | GREAT POINT PARTNERS LLC | 316K | $22.8M | +50.2% | 1.619% | 5.23% |
| 22 | Vestal Point Capital, LP | 285K | $20.5M | β | 1.459% | 0.57% |
| 23 | 22NW, LP | 281K | $20.2M | -15.1% | 1.439% | 13.86% |
| 24 | PRIMECAP MANAGEMENT CO/CA/ | 279K | $20.1M | -0.4% | 1.429% | 0.02% |
| 25 | ORBIMED ADVISORS LLC | 275K | $19.8M | β | 1.407% | 0.39% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in NKTR β a direct measure of their conviction.
Filings activity in NKTR during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new NKTR position in Q1 2026
Institutions that fully closed their NKTR position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 214 | +18% | 150.56% | +91.79 pp | $1.93B | +156% |
| Q4 2025 | 181 | +23% | 58.77% | 8.08 pp | $752M | 12% |
| Q3 2025 | 147 | +34% | 66.85% | +49.74 pp | $856M | +291% |
| Q2 2025 | 110 | 30% | 17.11% | +11.00 pp | $219M | +180% |
| Q1 2025 | 157 | +9.0% | 6.11% | 2.92 pp | $78M | 32% |
| Q4 2024 | 144 | +3.6% | 9.03% | 190.96 pp | $116M | 99% |
| Q3 2024 | 139 | +3.0% | 199.99% | +183.25 pp | $22.25B | +10282% |
| Q2 2024 | 135 | β | 16.74% | β | $214M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
No recent Form 4 insider transactions on file for NKTR.
Quick answers to the most common questions about buying NKTR stock.
Based on Q1 2026 13F filings, institutional ownership of Nektar Therapeutics stands at 150.6%, held across 214 reporting institutions.
FMR LLC is the largest reported institutional holder of NKTR, with approximately 4,303,188 shares worth $0.31B as of Q1 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of NKTR, including TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC.
Our composite Smart Money Score for NKTR is 67 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
72 institutions opened new positions in NKTR during Q1 2026, while 39 fully exited. 115 added to existing positions and 25 trimmed.
NKTR institutional ownership rose by 91.79 percentage points quarter-over-quarter, with a net change of β holders.
The top 10 institutions account for 54.5% of all reported 13F value in NKTR, and the top 25 account for 76.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.